CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea

  26 November 2019

CARB-X is awarding VenatoRx Pharmaceuticals, Inc. (Malvern, Pennsylvania, USA) up to US $4.1 million in non-dilutive funding, with the possibility of up to an additional US $8.9 million if certain project milestones are met, to develop a new class of oral antibiotics to treat infections caused by multi-drug-resistant (MDR) Neisseria gonorrhoeae.

Health officials have identified MDR gonorrhea, a sexually transmitted bacteria, as an urgent global public health threat, exacerbated by limited diagnostics and treatment options. Each year, an estimated 78 million people are infected with gonorrhea, which can infect the genitals, rectum and throat, according to the World Health Organization (WHO). Additionally, gonorrhea can cause pelvic inflammatory disease, ectopic pregnancy and infertility, as well as an increased risk of HIV. In a survey of 77 countries, WHO data show that antibiotic resistance is making gonorrhea much harder and sometimes impossible to treat ― 97% reported instances of drug-resistance to commonly used treatment regimens and 66% to cephalosporins, the remaining option for treatment.

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!